Company profile

The establishment of Pronexus Analytical AB in 2003 was preceded by a long-term scientific collaboration between the company founders, Prof. Kjell Fuxe, Prof. Urban Ungerstedt and Dr. Jan Kehr affiliated with the Department of Neuroscience and Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm. Pronexus is a privately owned fully proprietary and independent preclinical contract research organization.

 company leaflet.pdf (Download)

Pronexus offers advanced services and collaborative projects focused on CNS pharmacology, neurochemistry and neurophysiology in experimental disease models. Pronexus core expertise is focused on in vivo techniques for monitoring neurotransmitter release and metabolism, animal models of CNS disorders, PK/PD studies and testing the implantable medical devices and drug delivery systems. The bioanalytical services include high-sensitive HPLC techniques and immunoassays for determination of neurotransmitters and other neuroactive molecules, as well as metabolites and drug levels in the microdialysis samples, plasma, CSF, cell lysates and brain tissue extracts. Pronexus together with its strategic partner CMA/Microdialysis AB possess world leading expertise and know-how in preclinical and clinical microdialysis and allied analytical techniques. Pronexus bioanalytical laboratory and the animal research facility are GLP-compliant with full regulatory approvals. All services provided by Pronexus Analytical are carried-out under strictly professional non-disclosure agreements.
In addition, Pronexus Analytical AB offers contract research services and instruments for in vivo biosensor technology (manufactured by Quanteon LLC, USA). Implantable biosensors allow real time monitoring on second-by-second basis of neurotransmitter release and reuptake in anaesthetized and awake animals, as well as, in brain slices and in combination with electrophysiological recordings.

Personnel

The team of senior scientists (5 of them with PhD degree) at Pronexus Analytical and collaborators at Karolinska Institutet comprise an internationally recognized group in the field of experimental neuropharmacology and neurodegenerative models with focus on microdialysis, biosensors, neurophysiology and development of high-sensitive HPLC techniques for neurochemical analysis. Collectively we have more than 100 years of research experience both in academia and industry.

Partners

CMA Microdialysis (www.microdialysis.com)
Quanteon (http://www.quanteon.cc)
Scanbur (www.scanbur.eu)